XML 31 R18.htm IDEA: XBRL DOCUMENT v3.21.1
GOODWILL AND INTANGIBLE ASSETS
 12 Months Ended
Apr. 03, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETSEffective as of March 31, 2019, the Company revised the composition of its reportable segments to align with its three global business units, Plasma, Blood Center and Hospital. Refer to Note 18, Segment and Enterprise-Wide Information, for additional information regarding the change in the Company's reportable segments.
A reporting unit is defined as an operating segment or one level below an operating segment, referred to as a component. The Company aggregates components within an operating segment that have similar economic characteristics. Consistent with its reportable segments, reporting units for purposes of assessing goodwill impairment have also been reorganized based on business unit and include: Plasma, Blood Center and Hospital.

To determine the amount of goodwill within each of the new reporting units, the Company reallocated, on a relative fair value basis, $84.0 million of goodwill previously allocated to the former Europe, APAC and Japan reporting units to the new global reporting units. In addition, the $126.8 million of goodwill previously allocated to the former North America reporting units was reallocated to each new respective global reporting unit.

The following represents the Company's goodwill balance by new global reportable segment for fiscal 2021 and 2020. The prior period information has been restated to conform to the current presentation:
(In thousands)PlasmaBlood CenterHospitalTotal
Carrying amount as of March 30, 2019$28,979 $36,666 $145,174 $210,819 
Currency translation— (34)(133)(167)
Carrying amount as of March 28, 202028,979 36,632 145,041 210,652 
Divestitures— (2,181)(2,853)(5,034)
Acquisitions— — 259,788 259,788 
Currency translation64 77 897 1,038 
Carrying amount as of April 3, 2021$29,043 $34,528 $402,873 $466,444 

The results of the Company's goodwill impairment test performed in the fourth quarter of fiscal 2021, 2020 and 2019 indicated that the estimated fair value of all reporting units exceeded their respective carrying values. There were no reporting units at risk of impairment as of the fiscal 2021, 2020 and 2019 annual test dates.

The gross carrying amount of intangible assets and the related accumulated amortization as of April 3, 2021 and March 28, 2020 is as follows:
(In thousands)Gross Carrying
Amount		Accumulated
Amortization		Net
As of April 3, 2021  
Amortizable:
Patents$10,482 $8,897 $1,585 
Capitalized software71,575 43,858 27,717 
Other developed technology381,166 95,518 285,648 
Customer contracts and related relationships204,701 168,446 36,255 
Trade names9,516 3,921 5,595 
Total$677,440 $320,640 $356,800 
Non-amortizable:
In-process software development$4,007 
In-process patents4,676 
Total$8,683 
(In thousands)Gross Carrying
Amount		Accumulated
Amortization		Net
As of March 28, 2020  
Amortizable:
Patents$9,878 $8,653 $1,225 
Capitalized software76,740 43,022 33,718 
Other developed technology138,283 81,822 56,461 
Customer contracts and related relationships193,797 158,890 34,907 
Trade names5,141 4,555 586 
Total$423,839 $296,942 $126,897 
Non-amortizable:
In-process software development$2,563 
In-process patents3,646 
Total$6,209 

During the fourth quarter of fiscal 2021, the Company acquired Cardiva and recorded $230.3 million of developed technology, $18.2 million of customer relationships, and $5.4 million of trademarks based on our preliminary purchase accounting valuation.

During the first quarter of fiscal 2021, the Company acquired enicor and recorded $13.4 million of developed technology, $0.3 million of customer relationships, and $0.3 million of trademarks.

Refer to Note 4, Acquisitions, for additional information regarding these acquisitions.

Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationships and trade names. The estimated useful lives for all of these intangible assets are approximately 5 to 15 years. The changes to the net carrying value of the Company's intangible assets from March 28, 2020 to April 3, 2021 reflect the impact of acquisitions and investments in capitalized software, partially offset by amortization expense.

Aggregate amortization expense for amortized intangible assets for fiscal 2021, 2020, and 2019 was $41.2 million, $34.2 million and $32.6 million, respectively. There were no intangible asset impairments during fiscal 2021, 2020, and 2019.
Future annual amortization expense on intangible assets is estimated to be as follows:
(In thousands)
Fiscal 2022$53,672 
Fiscal 2023$39,371 
Fiscal 2024$34,937 
Fiscal 2025$27,582 
Fiscal 2026$22,247 

For costs incurred related to the development of software to be sold, leased, or otherwise marketed, the Company applies the provisions of ASC Topic 985-20, Software - Costs of Software to be Sold, Leased or Marketed, which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers. The costs capitalized for each project are included in intangible assets in the consolidated financial statements.
The Company capitalized $4.2 million and $3.9 million in software development costs for ongoing initiatives during fiscal 2021 and 2020, respectively. At April 3, 2021 and March 28, 2020, the Company had a total of $75.6 million and $79.3 million of software costs capitalized, of which $4.0 million and $2.6 million are related to in process software development initiatives, respectively, and the remaining balance represents in-service assets that are being amortized over their useful lives. Amortization expense for capitalized software was $7.8 million, $8.2 million, and $7.6 million for the fiscal years ended April 3, 2021, March 28, 2020, and March 30, 2019, respectively.